{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T10:27:02Z","timestamp":1697884022688},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00059-016-4505-6","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T08:24:21Z","timestamp":1479111861000},"page":"671-676","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ESC-Leitlinien 2016\u00a0\u2013 Dyslipid\u00e4mien"],"prefix":"10.1007","volume":"41","author":[{"given":"D.","family":"Sinning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"issue":"23","key":"4505_CR1","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1056\/NEJMsa053935","volume":"356","author":"ES Ford","year":"2007","unstructured":"Ford ES, Ajani UA, Croft JB et al\u00a0(2007) Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000. N Engl J Med 356(23):2388\u20132398. doi: 10.1056\/NEJMsa053935","journal-title":"N Engl J Med"},{"issue":"40","key":"4505_CR2","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","volume":"36","author":"N Townsend","year":"2015","unstructured":"Townsend N, Nichols M, Scarborough P, Rayner M (2015) Cardiovascular disease in Europe\u2013epidemiological update 2015. Eur Heart J 36(40):2696\u20132705. doi: 10.1093\/eurheartj\/ehv428","journal-title":"Eur. Heart J."},{"key":"4505_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G et al\u00a0(2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. doi: 10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"issue":"18","key":"4505_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Angelantonio Di","year":"2009","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P et al\u00a0(2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18):1993\u20132000. doi: 10.1001\/jama.2009.1619","journal-title":"JAMA"},{"issue":"14","key":"4505_CR5","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G et al\u00a0(2011) ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769\u20131818. doi: 10.1093\/eurheartj\/ehr158","journal-title":"Eur. Heart J."},{"key":"4505_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.018","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G et al\u00a0(2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281\u2013344. doi: 10.1016\/j.atherosclerosis.2016.08.018","journal-title":"Atherosclerosis"},{"issue":"29","key":"4505_CR7","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et al\u00a0(2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315\u20132381. doi: 10.1093\/eurheartj\/ehw106","journal-title":"Eur. Heart J."},{"issue":"24","key":"4505_CR8","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB Jorgensen","year":"2013","unstructured":"Jorgensen AB, Frikke-Schmidt R, West AS et al\u00a0(2013) Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34(24):1826\u20131833. doi: 10.1093\/eurheartj\/ehs431","journal-title":"Eur. Heart J."},{"issue":"3","key":"4505_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/157016111795495549","volume":"9","author":"GD Kolovou","year":"2011","unstructured":"Kolovou GD, Mikhailidis DP, Kovar J et al\u00a0(2011) Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9(3):258\u2013270","journal-title":"Curr Vasc Pharmacol"},{"issue":"3","key":"4505_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016111795495530","volume":"9","author":"C Mihas","year":"2011","unstructured":"Mihas C, Kolovou GD, Mikhailidis DP et al\u00a0(2011) Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 9(3):271\u2013280","journal-title":"Curr Vasc Pharmacol"},{"issue":"9943","key":"4505_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626\u2013635. doi: 10.1016\/S0140-6736(14)61177-6","journal-title":"Lancet"},{"issue":"5","key":"4505_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470\u2013477. doi: 10.1016\/j.jacc.2013.09.038","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"4505_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg F, Utermann G (2013) Lipoprotein(a): resurrected by genetics. J\u00a0Intern Med 273(1):6\u201330. doi: 10.1111\/j.1365-2796.2012.02592.x","journal-title":"J. Intern. Med."},{"issue":"23","key":"4505_CR14","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K et al\u00a0(2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844\u20132853. doi: 10.1093\/eurheartj\/ehq386","journal-title":"Eur. Heart J."},{"issue":"45","key":"4505_CR15","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE et al\u00a0(2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34(45):3478\u20133490a. doi: 10.1093\/eurheartj\/eht273","journal-title":"Eur. Heart J."},{"issue":"11","key":"4505_CR16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Pyorala K, Fitzgerald AP et al\u00a0(2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987\u20131003","journal-title":"Eur. Heart J."},{"issue":"25 Suppl 2","key":"4505_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et al\u00a0(2014) 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):1\u201345. doi: 10.1161\/01.cir.0000437738.63853.7a","journal-title":"Circulation"},{"issue":"9976","key":"4505_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Cholesterol Treatment Trialists (CTT) Collaboration, Fulcher J, O\u2019Connell R, Voysey M et al\u00a0(2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976):1397\u20131405. doi: 10.1016\/S0140-6736(14)61368-4","journal-title":"Lancet"},{"issue":"9841","key":"4505_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L et al\u00a0(2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581\u2013590. doi: 10.1016\/S0140-6736(12)60367-5","journal-title":"Lancet"},{"issue":"25","key":"4505_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP et al\u00a0(2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u20132397. doi: 10.1056\/NEJMoa1410489","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"4505_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S et al\u00a0(2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64(5):485\u2013494. doi: 10.1016\/j.jacc.2014.02.615","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"4505_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35(2):139\u2013151. doi: 10.1111\/j.1365-2710.2009.01085.x","journal-title":"J Clin Pharm Ther"},{"issue":"7404","key":"4505_CR23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326(7404):1423. doi: 10.1136\/bmj.326.7404.1423","journal-title":"BMJ"},{"issue":"1","key":"4505_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS et al (2013) Effect of statins on skeletal muscle function. Circulation 127(1):96\u2013103. doi: 10.1161\/CIRCULATIONAHA.112.136101","journal-title":"Circulation"},{"key":"4505_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw480","author":"U Landmesser","year":"2016","unstructured":"Landmesser U, Chapman MJ, Farnier M et al\u00a0(2016) European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. doi: 10.1093\/eurheartj\/ehw480","journal-title":"Eur. Heart J."},{"issue":"1","key":"4505_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11209150-000000000-00000","volume":"12","author":"KA Lyseng-Williamson","year":"2012","unstructured":"Lyseng-Williamson KA (2012) Ezetimibe\/simvastatin: a guide to its clinical use in hypercholesterolemia. Am J Cardiovasc Drugs 12(1):49\u201356. doi: 10.2165\/11209150-000000000-00000","journal-title":"Am J Cardiovasc Drugs"},{"issue":"15","key":"4505_CR27","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","volume":"106","author":"T Sudhop","year":"2002","unstructured":"Sudhop T, Lutjohann D, Kodal A et al\u00a0(2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106(15):1943\u20131948","journal-title":"Circulation"},{"key":"4505_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","volume":"54","author":"GD Norata","year":"2014","unstructured":"Norata GD, Tibolla G, Catapano AL (2014) Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 54:273\u2013293. doi: 10.1146\/annurev-pharmtox-011613-140025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"23","key":"4505_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M et al\u00a0(2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63(23):2531\u20132540. doi: 10.1016\/j.jacc.2014.03.018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"4505_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fca\u00a0.14.82","volume":"11","author":"EM Roth","year":"2015","unstructured":"Roth EM, McKenney JM (2015) ODYSSEY MONO: effect of alirocumab 75\u202fmg subcutaneously every 2\u00a0weeks as monotherapy versus ezetimibe over 24\u00a0weeks. Future Cardiol 11(1):27\u201337. doi: 10.2217\/fca_.14.82","journal-title":"Future Cardiol"},{"issue":"16","key":"4505_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M et al\u00a0(2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499. doi: 10.1056\/NEJMoa1501031","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"4505_CR32","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500\u20131509. doi: 10.1056\/NEJMoa1500858","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"4505_CR33","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/M15-2994","volume":"164","author":"EP Navarese","year":"2016","unstructured":"Navarese EP, Kolodziejczak M, Kereiakes DJ et al (2016) Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a\u00a0narrative review. Ann Intern Med 164(9):600\u2013607. doi: 10.7326\/M15-2994","journal-title":"Ann. Intern. Med."}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4505-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:31:46Z","timestamp":1498347106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["4505"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4505-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]}}}